Amgen Inc. (NASDAQ:AMGN) Shares Sold by Secure Asset Management LLC

Secure Asset Management LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,157 shares of the medical research company’s stock after selling 91 shares during the quarter. Secure Asset Management LLC’s holdings in Amgen were worth $672,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the 4th quarter valued at approximately $25,000. Pinney & Scofield Inc. purchased a new position in shares of Amgen during the 4th quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC purchased a new position in shares of Amgen during the 4th quarter valued at approximately $34,000. Finally, Atala Financial Inc purchased a new position in shares of Amgen during the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Mizuho increased their target price on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Guggenheim assumed coverage on Amgen in a research report on Tuesday, May 20th. They set a “neutral” rating and a $288.00 target price on the stock. Piper Sandler decreased their target price on Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research report on Friday, May 16th. Finally, Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average target price of $309.22.

Amgen Stock Down 0.9%

Shares of AMGN opened at $287.01 on Thursday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $154.33 billion, a PE ratio of 38.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The stock has a fifty day simple moving average of $282.39 and a two-hundred day simple moving average of $285.31. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company earned $3.96 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.